GeneDx (WGS) Jefferies London Healthcare Conference 2024 summary

Mission and vision

• Aims to diagnose genetic diseases as early as possible to enable timely intervention and halt disease progression.

• Focused on making genetic testing accessible at birth, with foundational work in large-scale newborn screening studies.

• Seeks to shift the standard of care from trial-and-error to upfront definitive genetic testing.

• Targets a large and growing market, especially in pediatric and rare diseases, with one in ten Americans affected.

• Envisions genetic testing becoming synonymous with symptom presentation, expanding beyond pediatrics.

Market opportunity and growth

• Estimates a $3 billion pediatric market, with potential to expand to $30 billion as testing becomes more widespread.

• Currently leads in clinical exome testing, with 80% market share, and is expanding into NICU with rapid whole genome products.

• Outpatient segment is the main focus, but NICU and broader clinician groups are targeted for future growth.

• Recent partnerships and new tools aim to break down access barriers and support biopharma collaborations.

Financial performance and profitability

• Achieved profitability in Q3, with continued revenue growth and improved gross margins.

• Raised annual revenue guidance to $284–$290 million.

• Mix shift toward exome and genome testing, which have 70% gross margins, is a key driver of profitability.

• Ongoing cost reductions in lab processes and automation are expected to further improve margins.